UNIVERSAL BIOSENSORS SHARES SURGE AFTER FDA APPROVAL

Written on the 5 October 2016

UNIVERSAL BIOSENSORS SHARES SURGE AFTER FDA APPROVAL UNIVERSAL Biosensors (ASX:UBI) is trading up 16.95 per cent today following the US Food and Drug Administration's approval of Siemens Healthineers' Xprecia Stride Coagulation Analyzer.

The hand-held device uses test strips developed and manufactured by UBI at its Rowville facility, in Victoria, to help monitor and assess patients taking the anticoagulation drug warfarin.

Warfarin is a blood thinner and its use must be monitored carefully, as too much of the drug can lead to uncontrolled bleeding, while too little can lead to a blood clot.

The worldwide point-of-care market for coagulation testing was estimated to be worth around US$1 billion in 2014 and is forecast to grow 9 per cent per annum to $US1.4 billion by 2018.

UBI executive chairman Andrew Denver says he is thrilled patients in the US will have access to this "exceptional" device.

"We look forward to working with Siemens to help establish its place in the US market," says Denver.

The Xprecia Stride analyser was commercially launched in Europe in May 2015.

Universal Biosensors released its results for the first half of 2016 in late July, and they showed a 41 per cent growth in revenue to $10.5 million compared to the previous corresponding period.

However, revenue from sales of the Xprecia Stride Coagulation Analyzer were down 56 per cent on the pcp.

The company gets most of its revenue from its partnership with LifeScan, for which it provides its One Touch Verio blood glucose test strips.

Overall, the company made a loss of $1.2 million in the first half of this year.



Latest News

WOOLWORTHS CLAIMS LEGAL VICTORY IN STOUSH WITH LOWE'S

SUPERMARKET giant Woolworths (ASX: WOW) has been given the go-ahead to sell its Masters property assets after winn...

DOMINO'S PIZZA EMPLOYEES OFFERED A SLICE OF THE PIE

DOMINO'S Pizza (ASX: DMP) has launched an employee share acquisition plan which will give its 26,000 staff the...

PRICELINE STORE ROLLOUT BOOSTS API'S FULL YEAR PROFIT FORECAST

Australian Pharmaceutical Industries (ASX: API) has booked a rise in half year net profit of $29.1 million on the bac...

CITY DWELLERS SETTING EYES ON REDCLIFFE AS PROPERTY SEACHANGE BECKONS

IT MAY be cool by the sea at Redcliffe, however strong sales at Kyko Group's Mon Komo development prove that t...

Related News

FURNITURE DISRUPTOR SET TO SHARE HIS ONE OF A KIND BUSINESS MODEL

IT'S no secret that Australians love homemaking. Their ceaseless quest to create the perfect place to call hom...

WEEDING OUT THE ASX'S BURGEONING CANNABIS TREND: 8 COMPANIES TO WATCH

A NICHE is budding on the ASX in the form of medical cannabis, an industry which has been on the country's rad...

FRESH CLASS ACTION TO REVEAL ANOTHER SIDE OF SLATER AND GORDON DOWNFALL

ACA LAWYERS has issued a formal letter of demand to Andrew Grech (pictured), managing director of Slater and Gordo...

STARSHIPS WERE MEANT TO DELIVER DOMINO'S PIZZA

NICKI Minaj may have been off the mark when she declared 'starships were meant to fly'. However, she m...

EVENTS COMING UP

 

Contact us

Email News Update Sign Up Contact Details
Subscriptions

PO Box 2087
Brisbane QLD 4001

LoginTell a FriendSign Up to Newsletter